Baltimore's Opioid Victory: A $266 Million Boost for Recovery
Wednesday, Nov 13, 2024 12:02 pm ET
4min read Baltimore has scored a significant victory in its opioid litigation, with a jury awarding the city $266 million in damages against opioid distributors McKesson and AmerisourceBergen. This substantial sum, which brings Baltimore's total restitution to over $668.5 million, will be allocated through Mayor Brandon M. Scott's executive order, funding prevention, treatment, and recovery services. The city's comprehensive approach to addressing the opioid epidemic includes collaboration with community organizations, substance use treatment centers, and investments in infrastructure to support a healthier Baltimore.
The $266 million award follows a six-week trial during which lawyers for the city argued that the two companies focused more on profit than public health, alleging that they shipped millions of opioid pills into the city, ignoring their addictive properties. The oversupply of pills led residents to turn to more potent drugs like fentanyl and heroin, the city argued. The companies, on the other hand, argued they acted within their rights by selling approved painkillers to licensed pharmacies and denied any responsibility for any illegal drug trade.
The verdict sends a strong signal to other cities and states pursuing similar litigation, potentially emboldening them to seek higher damages and settle for more favorable terms. Moreover, the jury's finding that the companies fueled the opioid epidemic by prioritizing profits over public health sets a precedent for future cases. As Baltimore's total restitution reaches over $668.5 million, other jurisdictions may follow its lead in using these funds to address the crisis and invest in recovery programs.
The awarded funds will complement existing initiatives and resources, enabling the city to expand its reach and intensify its response to the crisis. Mayor Scott anticipates that this verdict marks just the beginning of the more significant battle against opioid distributors, with an upcoming abatement proceeding scheduled for December. The city aims to address the comprehensive harm that the opioid crisis has inflicted upon its communities and to honor the memory of lost lives.
In conclusion, Baltimore's opioid case victory against McKesson and AmerisourceBergen is a crucial step in combating the opioid epidemic. The $266 million award, along with the city's strategic approach to litigation and allocation of funds, sets a precedent for other jurisdictions and demonstrates a commitment to addressing the crisis and investing in recovery programs. As the city continues its fight against opioid distributors, it remains dedicated to using these funds to save lives and build a healthier Baltimore.
The $266 million award follows a six-week trial during which lawyers for the city argued that the two companies focused more on profit than public health, alleging that they shipped millions of opioid pills into the city, ignoring their addictive properties. The oversupply of pills led residents to turn to more potent drugs like fentanyl and heroin, the city argued. The companies, on the other hand, argued they acted within their rights by selling approved painkillers to licensed pharmacies and denied any responsibility for any illegal drug trade.
The verdict sends a strong signal to other cities and states pursuing similar litigation, potentially emboldening them to seek higher damages and settle for more favorable terms. Moreover, the jury's finding that the companies fueled the opioid epidemic by prioritizing profits over public health sets a precedent for future cases. As Baltimore's total restitution reaches over $668.5 million, other jurisdictions may follow its lead in using these funds to address the crisis and invest in recovery programs.
The awarded funds will complement existing initiatives and resources, enabling the city to expand its reach and intensify its response to the crisis. Mayor Scott anticipates that this verdict marks just the beginning of the more significant battle against opioid distributors, with an upcoming abatement proceeding scheduled for December. The city aims to address the comprehensive harm that the opioid crisis has inflicted upon its communities and to honor the memory of lost lives.
In conclusion, Baltimore's opioid case victory against McKesson and AmerisourceBergen is a crucial step in combating the opioid epidemic. The $266 million award, along with the city's strategic approach to litigation and allocation of funds, sets a precedent for other jurisdictions and demonstrates a commitment to addressing the crisis and investing in recovery programs. As the city continues its fight against opioid distributors, it remains dedicated to using these funds to save lives and build a healthier Baltimore.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.